KRAS and colorectal carcinoma: From the studies outlined above and given that a large proportion of CRC patients with KRAS WT tumors do not respond to cetuximab or panitumumab, it is clear that a simple mutational analysis is insufficient to predict responsiveness to such therapeutics.